Slingshot Insights

Catalyst

Slingshot members are tracking this event:

GITR and LSD1 programs to enter clinical trials in the first half of 2016.

Source Link:: http://seekingalpha.com/article/3889126-incyte-incy-herve-hoppenot-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

INCY

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details From the Q4 transcript, "the GITR and LSD1 programs are the latest additions to our development portfolio. And given that both INDs were cleared by the FDA, we expect both to enter clinical trials in the first half of 2016. "

http://seekingalpha....

Additional Relevant Details INCB59872 (LSD1) Acute myeloid leukemia, small cell lung cancer Phase 1/2 dose-escalation

INCAGN1876 (GITR,
co-developed with Agenus) Solid tumors Phase 1/2 expected to initiate in the first half of 2016 (occured on Jun 22)

http://phx.corporate...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 22, 2016

Occurred Source:

http://phx.corporate-ir.net/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=2179317

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Gitr, Lsd1, Clinical Trials, Targeted Therapy, Immuno-oncology